Nuformix achieves second milestone for NXP001, triggering £500,000 payment
Anita Riotta
Company News- 3 min read
14:00, 15th May 2019

Nuformix (NFX) FOLLOW has successfully completed a second development milestone for its NXP001 treatment, which has triggered a £500,000 payment from its Chinese licensing partner, Newsummit Biopharma (NSB).

Moreover, achieving a second milestone further validates Nuformix’s prototype NXP001 cocrystal formulations.

NXP001 is being developed as a treatment for chemotherapy-induced nausea and vomiting (CINV), a condition affecting around 70-80% of patients undergoing chemotherapy.

Shares in NFX are trading nearly 17% higher today at 6.95p following the news.

This payment brings the total sum NSB has paid Nuformix based on milestones to £1 million. An additional £2 million payment is expected, “dependant on relative human bioavailability results.”

Dr. Dan Gooding, CEO of Nuformix commented on the news, “The data generated was not only sufficient to trigger a second payment of £500k with NewsummitBio, but also gave us tremendous confidence to make the next step into human studies. 

We look forward to sharing human data very soon and continue to work closely with NSB, such is their commitment to the commercialisation of NXP001 and its understanding of the commercial opportunity in China.”

And the steady march towards bringing NXP001 to market in China encapsulates NFX’s recent strategy to gain access to more international markets. 

Last month, the company signed an agreement for the development, licensing and commercialisation of cannabinoid therapeutics with private Canadian company, Ebers Tech Inc, a deal containing up to £51 million of upfront R&D for NFX.

Hear more from CEO Dr. Dan Gooding on the company's asset and their strategy for commercialization in China

For more news and updates on Nuformix: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist